A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) (Formerly Called EB-1020) in Young Healthy Subjects
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 16
- 主要终点
- Number of participants with treatment emergent adverse events and serious adverse events
研究概览
简要总结
The purpose of this study is to investigate the safety, tolerance, food effect, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of extended release (XR) formulations of Centanafadine (CTN) in Young Healthy participants.
详细描述
The study will be divided into three parts: A, B, C.
Part A: Single Dose, extended release (XR) Formulation Selection. This part of the study is a single dose, open label, four-period crossover design in a group of 16 healthy participants.
Part B: Multiple Ascending Dose. Part B has been designed to assess the effect of multiple doses of one formulation of XR CTN. This part of the study will be a double-blind, randomized, placebo-controlled design.
Part C: Food Effect. Part C has been designed to determine the effect food has on XR CTN. The XR formulation and dose administered will be selected after review of Part B data. This part will be an open-label, two-period crossover design in a group of 16 healthy participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Body weight within the normal range for height (body mass index [BMI] between 19-30 kg/m2 inclusive);
- •Negative serum pregnancy test at Screening and negative urine pregnancy test at Day -1 for females of child bearing potential;
- •Women of child-bearing potential must agree to use adequate; contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy;
- •Be in general good health without clinically significant medical history;
- •Have clinical laboratory test results that are within the laboratory reference range; or if out of range are not clinically relevant and are acceptable to the Investigator and Sponsor medical representative;
- •Negative Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C Screening test;
- •Able and willing to give written informed consent.
排除标准
- •Use of any of the following medications will exclude a participant:
- •investigational compound within 30 days prior to Screening;
- •antipsychotic, anxiolytic, or sedative-hypnotic medication within 30 days prior to Screening;
- •any antidepressant medication within 30 days prior to Screening;
- •clonidine within 30 days prior to Screening;
- •cough/cold preparations containing stimulants/sympathomimetic agent within 7 days prior to Day -1;
- •norepinephrine reuptake inhibitors, such as tomoxetine (STRATTERA®) within 30 days prior to Day -1;
- •antihypertensive agents, including diuretics, are not permitted at any time prior to or during the study;
- •sedating antihistamines (as a single preparation or in combination) within 7 days prior to Day -1;
- •sympathomimetics, appetite suppressants, modafinil, methylphenidate, amphetamine and pemoline within 7 days prior to Day -1;
- •Use over the counter medications within 7 days of Investigational Product administration, with the exception of simple analgesics such as paracetamol, oral non-steroidal anti-inflammatory agents and the oral contraceptive pill (if applicable);
- •Use of any herbal preparations and melatonin is prohibited and should be discontinued prior to Day -
- •The process for discontinuing use of herbal preparations and melatonin prior to Day -1 is at the discretion of the Investigator;
- •A history of, or current evidence for, suicidal ideation, based upon clinical interview and the Columbia Suicide Severity Rating Scale (C-SSRS);
- •A history of known or suspected seizures, spasms, infantile spasms, febrile convulsions, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits);
- •Subject has a known history of hypertension or Subject has a supine systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. No more than one repeat measurement will be permitted;
- •Subject has a known history of orthostatic hypotension or has an orthostatic blood pressure (BP) drop of ≥20 mm Hg (based on the drop between supine and standing [3 minutes] SBP) at Screening or Day -1;
- •Note: The eligibility criteria list is not exhaustive.
研究组 & 干预措施
Arm 1
Participants will receive sustained release (SR) Tablet Formulation 1 (SR1) containing 100 mg of Centanafadine (CTN) (2 x 100 mg tablets taken orally by mouth [PO] in the morning at starting at approximately 7 am and 2 x 100 mg tablets PO 5 hours later) for a total daily dose (TTD) of 400 mg on Days 1, 4, 7, and 10.
干预措施: CTN SR1 (Drug)
Arm 2
Participants will receive extended release (XR) Tablet Formulation 1 (XR1) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
干预措施: CTN XR1 (Drug)
Arm 3
Participants will receive XR Tablet Formulation 2 (XR2) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
干预措施: CTN XR2 (Drug)
Arm 4
Participants will receive XR Tablet Formulation 3 (XR3) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
干预措施: CTN XR3 (Drug)
结局指标
主要结局
Number of participants with treatment emergent adverse events and serious adverse events
时间窗: Up to approximately 12 days
次要结局
- Maximum observed plasma concentration (Cmax) of Centanafadine (CTN) and metabolite(For Part A: From Day 1 to 12; For Part B: Day 1, Day 2, Day 4, Day 5, Day 6, and Day 7; For Part C: Day 1 to 6)
- Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) from AUC0-last +Clast/kel of CTN and metabolite(For Part A: From Day 1 to 12; For Part B: Day 1, Day 2, Day 4, Day 5, Day 6, and Day 7; For Part C: Day 1 to 6)
- Area under the plasma concentration-time curve from time zero until the last quantifiable time point (AUC0-last) of CTN and metabolite(For Part A: From Day 1 to 12; For Part B: Day 1, Day 2, Day 4, Day 5, Day 6, and Day 7; For Part C: Day 1 to 6)
- Apparent termination elimination rate constant (kel) of CTN and metabolite(For Part A: From Day 1 to 12; For Part B: Day 1, Day 2, Day 4, Day 5, Day 6, and Day 7; For Part C: Day 1 to 6)
- Apparent terminal elimination half-life (t1/2) of CTN and metabolite(For Part A: From Day 1 to 12; For Part B: Day 1, Day 2, Day 4, Day 5, Day 6, and Day 7; For Part C: Day 1 to 6)
- Dose normalized Cmax (Cmax/Dose) of CTN and metabolite(For Part A: From Day 1 to 12; For Part B: Day 1, Day 2, Day 4, Day 5, Day 6, and Day 7; For Part C: Day 1 to 6)
- Time to maximum plasma concentration (Tmax) of CTN and metabolite(For Part A: From Day 1 to 12; For Part B: Day 1, Day 2, Day 4, Day 5, Day 6, and Day 7; For Part C: Day 1 to 6)
- last measurable plasma concentration (Clast) of CTN and metabolite(For Part A: From Day 1 to 12; For Part B: Day 1, Day 2, Day 4, Day 5, Day 6, and Day 7; For Part C: Day 1 to 6)
- Dose normalized AUC (AUC/Dose) of CTN and metabolite(For Part A: From Day 1 to 12; For Part B: Day 1, Day 2, Day 4, Day 5, Day 6, and Day 7; For Part C: Day 1 to 6)